Exploring short-term responses to changes in the control strategy for chlamydia trachomatis (Q428305): Difference between revisions
From MaRDI portal
Created a new Item |
Changed an Item |
||
Property / review text | |||
Summary: Chlamydia has a significant impact on public health provision in the developed world. Using pair approximation equations we investigate the efficacy of control programmes for chlamydia on short time scales that are relevant to policy makers. We use output from the model to estimate critical measures, namely, prevalence, incidence, and positivity in those screened and their partners. We combine these measures with a costing tool to estimate the economic impact of different public health strategies. Increasing screening coverage significantly increases the annual programme costs whereas an increase in tracing efficiency initially increases annual costs but over time reduces costs below baseline, with tracing accounting for around 10\% of intervention costs. We found that partner positivity is insensitive to changes in prevalence due to screening, remaining at around 33\%. Whether increases occur in screening or tracing levels, the cost per treated infection increases from the baseline because of reduced prevalence. | |||
Property / review text: Summary: Chlamydia has a significant impact on public health provision in the developed world. Using pair approximation equations we investigate the efficacy of control programmes for chlamydia on short time scales that are relevant to policy makers. We use output from the model to estimate critical measures, namely, prevalence, incidence, and positivity in those screened and their partners. We combine these measures with a costing tool to estimate the economic impact of different public health strategies. Increasing screening coverage significantly increases the annual programme costs whereas an increase in tracing efficiency initially increases annual costs but over time reduces costs below baseline, with tracing accounting for around 10\% of intervention costs. We found that partner positivity is insensitive to changes in prevalence due to screening, remaining at around 33\%. Whether increases occur in screening or tracing levels, the cost per treated infection increases from the baseline because of reduced prevalence. / rank | |||
Normal rank | |||
Property / Mathematics Subject Classification ID | |||
Property / Mathematics Subject Classification ID: 92C50 / rank | |||
Normal rank | |||
Property / Mathematics Subject Classification ID | |||
Property / Mathematics Subject Classification ID: 93C95 / rank | |||
Normal rank | |||
Property / Mathematics Subject Classification ID | |||
Property / Mathematics Subject Classification ID: 91B99 / rank | |||
Normal rank | |||
Property / zbMATH DE Number | |||
Property / zbMATH DE Number: 6047862 / rank | |||
Normal rank |
Revision as of 22:17, 29 June 2023
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Exploring short-term responses to changes in the control strategy for chlamydia trachomatis |
scientific article |
Statements
Exploring short-term responses to changes in the control strategy for chlamydia trachomatis (English)
0 references
19 June 2012
0 references
Summary: Chlamydia has a significant impact on public health provision in the developed world. Using pair approximation equations we investigate the efficacy of control programmes for chlamydia on short time scales that are relevant to policy makers. We use output from the model to estimate critical measures, namely, prevalence, incidence, and positivity in those screened and their partners. We combine these measures with a costing tool to estimate the economic impact of different public health strategies. Increasing screening coverage significantly increases the annual programme costs whereas an increase in tracing efficiency initially increases annual costs but over time reduces costs below baseline, with tracing accounting for around 10\% of intervention costs. We found that partner positivity is insensitive to changes in prevalence due to screening, remaining at around 33\%. Whether increases occur in screening or tracing levels, the cost per treated infection increases from the baseline because of reduced prevalence.
0 references